TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells

Cancer Immunology, Immunotherapy

Volumn 62, Issue 8, 2013, Pages 1347-1357

  Stephenson, Ryan M ^a   Lim, Chwee Ming ^a   Matthews, Maura ^b   Dietsch, Gregory ^b   Hershberg, Robert ^b   Ferris, Robert L ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VentiRx   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

ADCC; Cetuximab; Head and neck cancer; Immunotherapy; TLR8; VTX 2337

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; FC RECEPTOR IIIA; GAMMA INTERFERON; INTERLEUKIN 12P40; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VTX 2337;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL; CD8+ T LYMPHOCYTE; CELL MATURATION; COCULTURE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; DEGRANULATION; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS; BENZAZEPINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; CROSS-PRIMING; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOGLOBULINS; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P40; KILLER CELLS, NATURAL; MEMBRANE GLYCOPROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOLL-LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880924865     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1437-3     Document Type: Article

References (32)

1. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28. doi: 10.1016/S1470-2045(09)70311-0
2. Ferris RL, Jaffee EM, Ferrone S (2010) Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28:4390-4399. doi: 10.1200/JCO.2009.27.6360
3. Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK (2011) Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 187:3383-3390. doi: 10.4049/jimmunol. 1003926
4. Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL (2011) Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 50:248-254. doi: 10.1007/s12026-011-8231-0
5. Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL (2009) Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58:1853-1864. doi: 10.1007/s00262-009-0697-4
6. Lopez-Albaitero A, Ferris RL (2007) Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 133:1277-1281. doi: 10.1001/archotol.133.12.1277
7. McDonnell AM, Robinson BW, Currie AJ (2010) Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin Dev Immunol:539519. doi: 10.1155/2010/539519
8. Schon MP, Schon M (2008) TLR7 and TLR8 as targets in cancer therapy. Oncogene 27:190-199. doi: 10.1038/sj.onc.1210913
9. Hamm S, Rath S, Michel S, Baumgartner R (2009) Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol 6:257-265. doi: 10.3109/15476910903286733
10. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL (2007) The frequency and suppressor function of CD4 + CD25highFoxp3 + T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6301-6311. doi: 10.1158/1078-0432.CCR-07-1403
11. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS (2007) First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 13:7119-7125. doi: 10.1158/1078-0432.CCR-07-1443
12. Dummer R, Hauschild A, Becker JC et al (2008) An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 14:856-864. doi: 10.1158/1078-0432.CCR-07-1938
13. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13:859-875. doi: 10.1634/theoncologist.2008-0097
14. Kawai T, Akira S (2007) TLR signaling. Semin Immunol 19:24-32. doi: 10.1016/j.smim.2006.12.004
15. Diebold SS (2008) Recognition of viral single-stranded RNA by toll-like receptors. Adv Drug Deliv Rev 60:813-823. doi: 10.1016/j.addr.2007.11.004
16. Lombardi V, Van Overtvelt L, Horiot S, Moingeon P (2009) Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4 + T cells. J Immunol 182:3372-3379. doi: 10.4049/jimmunol.0801969
17. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531-4537
18. Lu H, Dietsch GN, Matthews MA et al (2012) VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 18:499-509. doi: 10.1158/1078-0432.CCR-11-1625
19. Andrade Filho PA, Lopez-Albaitero A, Gooding W, Ferris RL (2010) Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother 33:83-91. doi: 10.1097/CJI.0b013e3181b8f421
20. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL (2004) Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 50:714-721. doi: 10.1016/j.jaad.2003.12.010
21. Oldfield V, Keating GM, Perry CM (2005) Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol 6:195-200; discussion 1-2
22. Sauder DN, Smith MH, Senta-McMillian T, Soria I, Meng TC (2003) Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 47:3846-3852
23. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM (2005) TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 175:1636-1642
24. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529. doi: 10.1126/science.1093620
25. Okamura H, Tsutsi H, Komatsu T et al (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378:88-91. doi: 10.1038/378088a0
26. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T (2010) Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol. doi: 10.1155/2010/832454
27. Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, Bittenbring J (2011) The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 118:4657-4662. doi: 10.1182/blood-2011-04-346411
28. Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14:3706-3715. doi: 10.1158/1078-0432.CCR-07-5126
29. Whiteside TL (1998) Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. Adv Exp Med Biol 451:167-171
30. Peng G, Guo Z, Kiniwa Y et al (2005) Toll-like receptor 8-mediated reversal of CD4 + regulatory T cell function. Science 309:1380-1384. doi: 10.1126/science.1113401
31. Hiroishi K, Eguchi J, Baba T et al (2010) Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol 45:451-458. doi: 10.1007/s00535-009-0155-2
32. Srivastava RM, Lee SC, Andrade Filho PA et al (2013) Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 19:1858-1872. doi: 10.1158/1078-0432.CCR-12-2426